Top Players In Clear After US Court Confirms Abiraterone Patent Is Invalid
The sole US patent listed against Janssen’s Zytiga abiraterone prostate-cancer treatment is invalid, the US Court of Appeals has confirmed after generics entered the market in November last year.
You may also be interested in...
Apotex has failed to convince a Canadian federal court that a patent protecting Janssen’s Zytiga abiraterone brand until August 2027 is invalid and not infringed by its proposed generic version of the prostate-cancer treatment.
Generics of Janssen’s Zytiga (abiraterone acetate) blockbuster could enter the US market imminently, after a US Court of Appeals refused twice in quick succession to grant the originator injunctions blocking such launches.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.